TAONas-LUAD (@TaonasL) header
TAONas-LUAD (@TaonasL) profile picture

Stay tuned for news about the TAONas-LUAD project

Barcelona
Joined July 2022
Our mission, team, and roadmap, all in one short video so you can get to know our project.
1
The NUMB gene, and a splicing error in its exon 9 that is linked to cancer cell growth, is the target of a new approach to treating lung adenocarcinoma. Read on to see why 👇🏼
8
Diving into aberrant splicing and RNA diseases 🔬 In this carousel, we explore what happens when post-transcriptional processing goes wrong, and how it connects to conditions like ALS, Myotonic Dystrophy, and lung cancer. Stay tuned for more on the science behind our research.
12
Today we launch a series on aberrant splicing and its role in genetic diseases. This first piece lays the foundation, starting with what alternative splicing is and how it works at the molecular level. 🔬 Stay tuned for more on the science behind our research.
5
7 April 2026 | #WorldHealthDay 🌍 At TAONas-LUAD, we #StandWithScience and support WHO’s mission for a healthier world. Advancing ASOs for RNA diseases, we aim to deliver personalised treatments globally with #AlternaTherapeutics.
11
New update on the @TaonasL website! Our latest blog revisits key concepts behind our research, from molecular biology basics to the role of alternative splicing in gene regulation and RNA-related diseases. Read more: taonas.eu/aberrant-splicing-…
7
TAONas-Talks | Episode 4 🎙️ We’re back with our researchers! Meet Jérémie Parot, Senior Research Scientist at @SINTEF, as he dives into LNP design for safe & efficient ASO delivery. From preclinical results to the future of drug delivery—don’t miss it!
7
Hard work pays off! 🚀 Proud to see Alterna Therapeutics (EIC Transition @TaonasL spin-off) named a Top 10 Company to Watch by @LSciNation. Big thanks to Maria Buxadé Fortuny for driving our RNA therapies forward. 2026 looks bright! ✨ 👉 blog.lifesciencenation.com/2…
5
TAONas-Talks | Ep. 3 🎙️ Meet Maria Buxade, CEO of Alterna Therapeutics, TAONas-LUAD’s future spin-off. With 25+ years in immunology & biotech leadership, Maria shares what led her to take the CEO role, investor feedback, project progress, and what’s next for Alterna Tx.
12
A special milestone for TAONas-LUAD 🚀 As the final year of our EIC Transition project ends, we reflect on 3.5+ years advancing antisense therapies for lung cancer. The journey continues beyond EIC funding—toward more tangible outcomes in 2026. Stay tuned & happy new year!
22
Happy holidays from the @TaonasL team! 🎄 Thank you for supporting our work on lung cancer. We’re taking a short break to recharge and will be back soon with renewed energy—continuing the fight against cancer with the power of science.
4
TAONas-LUAD ends soon after 3 years of EIC-backed work. Which has it been its main focus, continued by CRG spin-off “Alterna Therapeutics”?
0%ASO for aberrant splicing
0%Alzheimer diagnosis
0%ASO for brain tumours
0%Infectious diagnosis
0 votes • Final results
9
Maria Buxadé Fortuny, CEO of Alterna Therapeutics (soon-to-be @CRGenomica spin-off), will be at RESI London next week. A great chance to showcase our RNA-targeted therapeutic tech and connect with investors and partners. Attending RESI? Let’s meet!
1
9
🚀 TAONas-Talks Ep. 2 is out! Featuring Juan Valcárcel (@CRGenomica), a leading voice in #MolecularBiology and coordinator of @TaonasL. Don’t miss this conversation with interviewer Marc Dominguez! #TAONasTalks #CRG #LungCancerResearch
1
20
Hear his insights on: ✅Advances in lung adenocarcinoma research ✅CRG’s role in collaboration & innovation ✅The future of TAONas & spin-off Alterna Therapeutics
3
🔬 @SINTEF, one of Europe’s largest research institutes, has designed and optimized LNPs for targeted ASO delivery to lung tissue in @TaonasL 60× higher efficacy than naked ASOs in lung cancer models.
42
We’re heading to #BIOEurope2025 in Vienna. Maria Buxadé, CEO of our @TaonasL spin-off, will: • Build alliances with biotech and pharma leaders • Engage investors for our AI-powered RNA platform • Showcase our therapeutic vision for cancer and RNA diseases
1
34
🚀 Exciting news from Alterna Therapeutics! Our CEO Maria will attend the 21st Annual @OTSociety Meeting in Budapest (Oct 19–22) — the premier global event for RNA & antisense experts. Stay tuned for updates from #OTS2025!
1
1
1
281
🌍 @BIOSPAIN_AseBio 2025 (Oct 7–9, Barcelona) will gather 2,500+ biotech leaders & 1,000+ orgs worldwide. For Alterna Therapeutics, it’s a chance to spotlight our ASO therapies, engage KOLs & forge partnerships in the fast-growing RNA space. See you in Barcelona! #BIOSPAIN2025
16
🔬 Meet our coordinator: @CRGenomica in Barcelona! CRG, led by Dr. Juan Valcárcel’s lab, pioneers research on alternative splicing to drive new RNA-based therapies. Their expertise bridges discovery & application, from cancer biology to spin-off creation. #RNAtherapeutics
19